Serum microRNAs as biomarkers in patients undergoing prostate biopsy: Results from a prospective multi-center study

Anticancer Research

Volumn 34, Issue 2, 2014, Pages 665-670

  Westermann, Anna M ^a   Schmidt, Doris ^a   Holdenrieder, Stefan ^a   Moritz, Rudolf ^b   Semjonow, Axel ^b   Schmidt, Matthias ^c   Kristiansen, Glen ^a   Müller, Stefan C ^a   Ellinger, Jörg ^a  

^a UNIVERSITY HOSPITAL BONN   (Germany)

^b UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^c Ambulatory Urological Center   (Germany)

Author keywords

Biomarker; MicroRNA; MiR 141; MiR 26a 1; Prostate cancer; Serum

Indexed keywords

MICRORNA; MICRORNA 141; MICRORNA 26A; MICRORNA 26A 1; RNA; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; MIRN141 MICRORNA, HUMAN; MIRN26A MICRORNA, HUMAN; TUMOR MARKER;

ADULT; AGED; ARTICLE; BLOOD LEVEL; GENE; GLEASON SCORE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PROSPECTIVE STUDY; PROSTATE BIOPSY; PROSTATE CANCER; REAL TIME POLYMERASE CHAIN REACTION; RNA ISOLATION; BIOPSY; BLOOD; CANCER GRADING; GENETICS; MIDDLE AGED; MIR-141; MIR-26A-1; PATHOLOGY; PROSTATE TUMOR; SERUM;

BIOMARKER; MICRORNA; MIR-141; MIR-26A-1; PROSTATE CANCER; SERUM;

ADULT; AGED; BIOPSY; HUMANS; MALE; MICRORNAS; MIDDLE AGED; NEOPLASM GRADING; PROSPECTIVE STUDIES; PROSTATIC NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84897070909     PISSN: 02507005     EISSN: 17917530     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Farazi TA, Hoell JI, Morozov P and Tuschl T: MicroRNAs in human cancer. Adv Exp Med Biol 774: 1-20, 2013.
2. Friedman RC, Farh KK, Burge CB and Bartel DP: Most mammalian mRNAs are conserved targets of microRNAs. Genome Res 19(1): 92-105, 2009.
3. Iorio MV and Croce CM: Causes and consequences of microRNA dysregulation. Cancer J 18(3): 215-222, 2012.
4. Ozen M, Creighton CJ, Ozdemir M and Ittmann M: Widespread deregulation of microRNA expression in human prostate cancer. Oncogene 27(12): 1788-1793, 2008.
5. Volinia S, Calin GA, Liu CG, Ambs S, Cimmino A, Petrocca F, Visone R, Iorio M, Roldo C, Ferracin M, Prueitt RL, Yanaihara N, Lanza G, Scarpa A, Vecchione A, Negrini M, Harris CC and Croce CM: A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci USA 103(7): 2257-2261, 2006.
6. Porkka KP, Pfeiffer MJ, Waltering KK, Vessella RL, Tammela TL and Visakorpi T: MicroRNA expression profiling in prostate cancer. Cancer Res 67(13): 6130-6135, 2007.
7. Shen J, Stass SA and Jiang F: MicroRNAs as potential biomarkers in human solid tumors. Cancer Lett 329(2): 125-136, 2013.
8. Lawrie CH, Gal S, Dunlop HM, Pushkaran B, Liggins AP, Pulford K, Banham AH, Pezella F, Boultwood J, Wainscoat JS, Hatton CS and Harris AL: Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma. Br J Haematol 141(5): 672-675, 2008.
9. Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, Peter-son A, Noteboom J, O'Briant KC, Allen A, Lin DW, Urban N, Drescher CW, Knudsen BS, Stirewalt DL, Gentleman R, Vessella RL, Nelson PS, Martin DB and Tewari M: Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA 105(30): 10513-10518, 2008.
10. Schaefer A, Jung M, Mollenkopf HJ, Wagner I, Stephan C, Jentzmik F, Miller K, Lein M, Kristiansen G and Jung K: Diagnostic and prognostic implications of microRNA profiling in prostate carcinoma. Int J Cancer 126(5): 1166-1176, 2010.
11. Moltzahn F, Olshen AB, Baehner L, Peek A, Fong L, Stöppler H, Simko J, Hilton JF, Car-roll P and Blelloch R: Microfluidic-based multiplex qRT-PCR identifies diagnostic and prog-nostic microRNA signatures in the sera of prostate cancer patients. Cancer Res 71(2): 550-560, 2011.
12. Zheng H, Zhang L, Zhao Y, Yang D, Song F, Wen Y, Hao Q, Hu Z, Zhang W and Chen K: Plasma miRNAs as Diagnostic and Prognostic Biomarkers for Ovarian Cancer. PLoS One 8(11): e77853, 2013.
13. Cheng H, Zhang L, Cogdell DE, Zheng H, Schetter AJ, Nykter M, Harris CC, Chen K, Hamilton SR and Zhang W: Circulating plasma MiR-141 is a novel biomarker for metastatic colon cancer and predicts poor prognosis. PLoS One 6(3): e17745, 2011.
14. Healy NA, Heneghan HM, Miller N, Osborne CK, Schiff R and Kerin MJ: Systemic mir-nas as potential biomarkers for malignancy. Int J Cancer 131(10): 2215-2222, 2012.
15. Lodes MJ, Caraballo M, Suciu D, Munro S, Kumar A and Anderson B: Detection of can-cer with serum miRNAs on an oligonucleotide microarray. PLoS One 4(7): e6229, 2009.
16. Schröder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, Kwiatkowski M, Lujan M, Lilja H, Zappa M, Denis LJ, Recker F, Berenguer A, Määttänen L, Bangma CH, Aus G, Villers A, Rebillard X, van der Kwast T, Blijenberg BG, Moss SM, de Koning HJ, Auvinen A and ERSPC Investigators: Screening and prostate-cancer mortality in a ran-domized European study. N Engl J Med 360(13): 1320-1328, 2009.
17. Andriole GL, Crawford ED, Grubb RL 3rd, Buys SS, Chia D, Church TR, Fouad MN, Gelmann EP, Kvale PA, Reding DJ, Weissfeld JL, Yokochi LA, O'Brien B, Clapp JD, Rath-mell JM, Riley TL, Hayes RB, Kramer BS, Izmirlian G, Miller AB, Pinsky PF, Prorok PC, Gohagan JK, Berg CD and PLCO Project Team: Mortality results from a randomized pros-tate-cancer screening trial. N Engl J Med 360(13): 1310-1319, 2009.
18. Pinsky PF, Black A, Parnes HL, Grubb R, David Crawford E, Miller A, Reding D and Andriole G: Prostate cancer specific survival in the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial. Cancer Epidemiol 36(6): e401-406, 2012.
19. Strope SA and Andriole GL: Prostate cancer screening: current status and future perspec-tives. Nat Rev Urol 7(9): 487-493, 2010.
20. Sandblom G, Varenhorst E, Rosell J, Löfman O and Carlsson P: Randomised prostate can-cer screening trial: 20 year follow-up. BMJ 342: d1539, 2011.
21. Sandhu GS and Andriole GL: Overdiagnosis of prostate cancer. J Natl Cancer Inst Monogr 2012(45): 146-151, 2012.
22. Mahn R, Heukamp LC, Rogenhofer S, von Ruecker A, Müller SC and Ellinger J: Circulat-ing microRNAs (miRNA) in serum of patients with prostate cancer. Urology 77: 1265.e9-16, 2011.
23. Gonzales JC, Fink LM, Goodman OB Jr., Symanowski JT, Vogelzang NJ and Ward DC: Comparison of circulating MicroRNA 141 to circulating tumor cells, lactate dehydrogenase, and prostate-specific antigen for determining treatment response in patients with metastatic prostate cancer. Clin Genitourin Cancer 9(1): 39-45, 2011.
24. Brase JC, Johannes M, Schlomm T, Fälth M, Haese A, Steuber T, Beissbarth T, Kuner R and Sültmann H. Circulating miRNAs are correlated with tumor progression in prostate can-cer. Int J Cancer 128(3): 608-616, 2011.
25. Yaman Agaoglu F, Kovancilar M, Dizdar Y, Darendeliler E, Holdenrieder S, Dalay N and Gezer U: Investigation of miR-21, miR-141, and miR-221 in blood circulation of patients with prostate cancer. Tumour Biol 32: 583-588, 2011.
26. Selth LA, Townley SL, Bert AG, Stricker PD, Sutherland PD, Horvath LG, Goodall GJ, Butler LM and Tilley WD: Circulating microRNAs predict biochemical recurrence in prostate cancer patients. Br J Cancer 109(3): 641-650, 2013.
27. Sanders I, Holdenrieder S, Walgenbach-Brünagel G, von Ruecker A, Kristiansen G, Müller SC and Ellinger J: Evaluation of reference genes for the analysis of serum miRNA in patients with prostate cancer, bladder cancer and renal cell carcinoma. J.Int J Urol 19(11): 1017-1025, 2012.
28. Bryant RJ, Pawlowski T, Catto JW, Marsden G, Vessella RL, Rhees B, Kuslich C, Visa-korpi T and Hamdy FC: Changes in circulating microRNA levels associated with prostate cancer. Br J Cancer 106(4): 768-774, 2012.
29. Wulfken LM, Moritz R, Ohlmann C, Holdenrieder S, Jung V, Becker F, Herrmann E, Walgenbach-Brünagel G, von Ruecker A, Müller SC and Ellinger J: MicroRNAs in renal cell carcinoma: diagnostic implications of serum miR-1233 levels. PLoS One 6(9): e25787, 2011.
30. Hauser S, Wulfken LM, Holdenrieder S, Moritz R, Ohlmann CH, Jung V, Becker F, Herrmann E, Walgenbach-Brünagel G, von Ruecker A, Müller SC and Ellinger J: Analysis of serum microRNAs (miR-26a-2∗, miR-191, miR-337-3p and miR-378) as potential biomark-ers in renal cell carcinoma. Cancer Epidemiol 36(4): 391-394, 2012.
31. Scheffer AR, Holdenrieder S, Kristiansen G, von Ruecker A, Müller SC and Ellinger J: Circulating microRNAs in serum: novel biomarkers for patients with bladder cancer? World J Urol 2012 [Epub ahead of print].
32. Schiffgen M, Schmidt DH, von Rücker A, Müller SC and Ellinger J: Epigenetic regulation of microRNA expression in renal cell carcinoma. Biochem Biophys Res Commun 436(1): 79-84, 2013.